ClinicalTrials.gg
CompletedNCT05164341METRE-PLUpdated Nov 9, 2026

Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL

A Phase 3 interventional study of metreleptin and Placebo in Partial Lipodystrophy, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 31 sites in 9 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 3, Interventional, and Treatment

How we know

Updated Nov 9, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
69
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Study summary

This is a Phase III, double-blind, placebo-controlled, safety and efficacy study of daily SC metreleptin in subjects with Partial Lipodystrophy.

Read the detailed description

This Phase 3, randomised, multicentre, double-blind, placebo-controlled study is designed to evaluate the safety and efficacy of once-daily subcutaneous metreleptin in participants with partial lipodystrophy and associated metabolic complications. The study compares metreleptin with placebo over a 12-month treatment period, followed by an extension phase. The primary objective is to assess the effect of metreleptin on key metabolic parameters, including glycaemic control and hypertriglyceridemia.

Secondary objectives include evaluation of safety, tolerability, additional metabolic outcomes, liver-related parameters, and patient-reported outcomes in this rare disease population.

02

Conditions studied

  • Partial Lipodystrophy

Keywords

  • metreleptin
03

In context

Lead sponsor

Chiesi Farmaceutici S.p.A. is the lead sponsor of 185 studies on the registry; 22 are open to participants now.

Of its 18 completed or terminated interventional studies of FDA-regulated products, 11 (61%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Familial Partial Lipodystrophy (FPLD)
  • Subjects with poor metabolic control defined as:

≥7% (at Visit 1 and Visit 3) and/or Fasting TGs ≥500 mg/dL (5.65 mmol/L, at Visit 1 and Visit 3)

  • Patients should be receiving optimized stable therapy

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with metreleptin
  • Leptin levels >20.0 ng/mL
  • Acquired or radiation induced partial lipodystrophy (APL)

Other protocol defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
69 participants (actual)

Study arms

  • Active comparator
    metreleptin

    Metreleptin \[Recombinant-methionyl human Leptin; r-metHuLeptin\] for daily injection is a sterile, white, solid lyophilised cake

    Drug: metreleptin

  • Placebo comparator
    placebo

    Placebo for daily injection is a sterile, white, solid lyophilised cake

    Drug: Placebo

Interventions

  • Metreleptin is a recombinant human leptin analog that is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Change from baseline to month 6 in HbA1c in subjects with partial lipodystrophy (PL)

    To evaluate the efficacy (HbAa1c) of daily SC metreleptin treatment

    Time frame: 6 months

  2. Percent change from Baseline to month 6 in fasting TGs in subjects with partial lipodystrophy (PL)

    To evaluate the efficacy (TGs) of daily SC metreleptin treatment

    Time frame: 6 months

Secondary outcomes

  1. Safety analysis of AEs, AESIs, SAEs by treatment arm

    To evaluate the safety of daily SC metreleptin treatment in subjects with PL

    Time frame: 12 months

  2. Change from baseline to months 9 and 12 in HbA1c in subjects with partial lipodystrophy (PL)

    To assess the effect of metreleptin on HbA1c

    Time frame: 12 months

  3. Percent change from baseline to months 9 and 12 in fasting TGs in subjects with partial lipodystrophy (PL)

    To assess the effect of metreleptin on TGs

    Time frame: 12 months

  4. Change from Baseline to each assessment time point in quality of life (QoL) in all subjects

    To assess the effect of metreleptin on quality of life (QoL) in all subjects

    Time frame: 12 months

07

Study locations

31 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2021 to primary completion in Jul 2026, 54 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2021
First posted
Dec 20, 2021
StartActual
Dec 17, 2021
Primary completionActual
Jul 14, 2026
CompletionActual
Oct 6, 2026
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 9, 2026
Primary completion
Jul 21, 2026→Jul 14, 2026 (actual)
Nov 9, 2026
Study completion
Oct 31, 2026→Oct 6, 2026 (actual)
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Active, not recruiting→Completed
    Primary completion Jul 21, 2026→Jul 14, 2026 (now actual)
    Study completion Oct 31, 2026→Oct 6, 2026 (now actual)
    + 3 other changes: verification date, description and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05164341
Responsible party
Sponsor
First posted
Dec 20, 2021
Start date
Dec 17, 2021
Primary completion
Jul 14, 2026
Completion
Oct 6, 2026
Last update
Nov 9, 2026

Study contacts

Elif Oral
principal investigator · University of Michigan

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metreleptin

Start the discussion